TVARDI THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
TVARDI THERAPEUTICS, INC. (TVRD) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$3.69 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2025-05-13
- TVARDI THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$3.69M.
- TVARDI THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$5.19M.
- TVARDI THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$16.35M, a 306.73% decline year-over-year.
- TVARDI THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was $7.91M.
- TVARDI THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$15.78M.
- TVARDI THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$10.47M, a 120.81% decline from fiscal 2022.
- TVARDI THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $50.29M.
- TVARDI THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was -$18.23M, a 236.27% decline from fiscal 2020.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2025-03-31 | -$3.69M 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | -$15.78M 10-K · filed 2025-03-11 | |||
| 2024-09-30 | -$15.12M 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | -$2.94M 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | -$5.19M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$10.47M 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $634.00K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$3.99M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$16.35M 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $50.29M 10-K · filed 2025-03-11 | |||
| 2022-09-30 | $29.35M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $33.27M 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | $7.91M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$18.23M 10-K · filed 2024-03-06 | |||
| 2021-09-30 | -$8.69M 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | -$9.35M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$9.16M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $13.38M 10-K · filed 2023-03-06 | |||
| 2020-09-30 | $56.98M 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | $38.66M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | -$1.27M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $2.86M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $19.26M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | $3.41M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | -$893.00K 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $5.69M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $87.34M 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | $8.41M 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $2.49M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | -$3.40M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | -$300.00K 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | -$2.68M 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | -$6.79M 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | -$2.24M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |